ASPiRA Labs, a Vermillion company (NASDAQ: VRML), today announced it has signed an in-network, contracted agreement with TriCare South for ASPiRA’s U.S. FDA cleared, Centers for Medicare and Medicaid Services (CMS) covered, American College of Obstetricians and Gynecologists (ACOG) Level B recommended ovarian cancer risk assessment test, OVA1® (Multivariate Index Assay or MIA). TriCare South serves about 2.5 million beneficiaries in the states of Alabama, Arkansas, Florida, Georgia, Louisiana, Mississippi, Oklahoma, South Carolina, Tennessee, Texas (excluding El Paso) and Fort Campbell, Kentucky.
Links to multiple clinical studies showing OVA1 (MIA)’s strong performance over CA125 for earlier and improved detection can be found on our website:
http://vermillion.com/providers/ova-1/clinical-validation-studies/.
Related Coverage
- 32 Hospitals Settling Medicare Fraud Allegations Due to Whistleblower
- Blue Cross and Blue Shield of Texas Expands its Medicare Advantage Offerings
- Oklahomans Brace for Skyrocketing Increases on ACA Marketplace
For more reporting on this topic, see our Medicare news hub.